ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.
age older than 18 years old
received ECMO because of severe respiratory failure
anticoagulant contraindications
cerebral infarction or suspected patients
severe hypertension
women in gestational and lactational period